Astrocytes Downregulate Inflammation in Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome: Applicability to COVID-19
Background: An acute respiratory distress syndrome (ARDS) is caused by the increased amounts of pro-inflammatory cytokines and neutrophil-mediated tissue injury. To date, there is no effective treatment for the ARDS available, while the need for one is growing due to the most severe complications of...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-10-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2021.740071/full |
| _version_ | 1818401181721952256 |
|---|---|
| author | Michal Izrael Kfir Molakandov Ariel Revel Shalom Guy Slutsky Tehila Sonnenfeld Julia Miriam Weiss Michel Revel Michel Revel |
| author_facet | Michal Izrael Kfir Molakandov Ariel Revel Shalom Guy Slutsky Tehila Sonnenfeld Julia Miriam Weiss Michel Revel Michel Revel |
| author_sort | Michal Izrael |
| collection | DOAJ |
| description | Background: An acute respiratory distress syndrome (ARDS) is caused by the increased amounts of pro-inflammatory cytokines and neutrophil-mediated tissue injury. To date, there is no effective treatment for the ARDS available, while the need for one is growing due to the most severe complications of the current coronavirus disease-2019 (COVID-19) pandemic. The human astrocytes (AstroRx) have shown immunomodulatory properties in the central nervous system (CNS). This study aimed to evaluate the capacity of astrocytes to decrease lung inflammation and to be applied as a treatment therapy in ARDS.Methods: First, we assessed the ability of clinical-grade AstroRx to suppress T-cell proliferation in a mixed lymphocyte reaction test. Next, we tested the therapeutical potential of AstroRx cells in a lipopolysaccharide (LPS)-based ARDS mouse model by injecting AstroRx intravenously (i.v). We determined the degree of lung injury by using a severity scoring scale of 0–2, based on the American Thoracic Society. The scoring measured the presence of neutrophils, fibrin deposits, and the thickening of alveolar walls. The state of inflammation was further assessed by quantifying the immune-cell infiltration to the bronchoalveolar lavage fluid (BALF) and by the presence of proinflammatory cytokines and chemokines in the BALF and serum.Results: We detected that AstroRx cells were capable to suppress T-cell proliferation in vitro after exposure to the mitogen concanavalin A (ConA). In vivo, AstroRx cells were able to lower the degree of lung injury in LPS-treated animals compared with the sham injected animals (P = 0.039). In this study, 30% of AstroRx treated mice showed no lung lesions (responder mice), these mice presented a steady number of eosinophils, T cells, and neutrophils comparable with the level of naïve control mice. The inflammatory cytokines and chemokines, such as TNFα, IL1b, IL-6, and CXCL1, were also kept in check in responder AstroRx-treated mice and were not upregulated as in the sham-injected mice (P < 0.05). As a result, the LPS-treated ARDS mice had a higher survival rate when they were treated with AstroRx.Conclusions: Our results demonstrate that the immunosuppressive activity of AstroRx cells support the application of AstroRx cells as a cell therapy treatment for ARDS. The immunoregulatory activity may also be a part of the mechanism of action of AstroRx reported in the amyotrophic lateral sclerosis (ALS) neurodegenerative disease. |
| first_indexed | 2024-12-14T07:48:23Z |
| format | Article |
| id | doaj.art-4e669f64b52142248ccc4e18b56f57ea |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-14T07:48:23Z |
| publishDate | 2021-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-4e669f64b52142248ccc4e18b56f57ea2022-12-21T23:10:48ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2021-10-01810.3389/fmed.2021.740071740071Astrocytes Downregulate Inflammation in Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome: Applicability to COVID-19Michal Izrael0Kfir Molakandov1Ariel Revel2Shalom Guy Slutsky3Tehila Sonnenfeld4Julia Miriam Weiss5Michel Revel6Michel Revel7Research and Development Department at Kadimastem Ltd, Nes-Ziona, IsraelResearch and Development Department at Kadimastem Ltd, Nes-Ziona, IsraelResearch and Development Department at Kadimastem Ltd, Nes-Ziona, IsraelResearch and Development Department at Kadimastem Ltd, Nes-Ziona, IsraelResearch and Development Department at Kadimastem Ltd, Nes-Ziona, IsraelResearch and Development Department at Kadimastem Ltd, Nes-Ziona, IsraelResearch and Development Department at Kadimastem Ltd, Nes-Ziona, IsraelDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot, IsraelBackground: An acute respiratory distress syndrome (ARDS) is caused by the increased amounts of pro-inflammatory cytokines and neutrophil-mediated tissue injury. To date, there is no effective treatment for the ARDS available, while the need for one is growing due to the most severe complications of the current coronavirus disease-2019 (COVID-19) pandemic. The human astrocytes (AstroRx) have shown immunomodulatory properties in the central nervous system (CNS). This study aimed to evaluate the capacity of astrocytes to decrease lung inflammation and to be applied as a treatment therapy in ARDS.Methods: First, we assessed the ability of clinical-grade AstroRx to suppress T-cell proliferation in a mixed lymphocyte reaction test. Next, we tested the therapeutical potential of AstroRx cells in a lipopolysaccharide (LPS)-based ARDS mouse model by injecting AstroRx intravenously (i.v). We determined the degree of lung injury by using a severity scoring scale of 0–2, based on the American Thoracic Society. The scoring measured the presence of neutrophils, fibrin deposits, and the thickening of alveolar walls. The state of inflammation was further assessed by quantifying the immune-cell infiltration to the bronchoalveolar lavage fluid (BALF) and by the presence of proinflammatory cytokines and chemokines in the BALF and serum.Results: We detected that AstroRx cells were capable to suppress T-cell proliferation in vitro after exposure to the mitogen concanavalin A (ConA). In vivo, AstroRx cells were able to lower the degree of lung injury in LPS-treated animals compared with the sham injected animals (P = 0.039). In this study, 30% of AstroRx treated mice showed no lung lesions (responder mice), these mice presented a steady number of eosinophils, T cells, and neutrophils comparable with the level of naïve control mice. The inflammatory cytokines and chemokines, such as TNFα, IL1b, IL-6, and CXCL1, were also kept in check in responder AstroRx-treated mice and were not upregulated as in the sham-injected mice (P < 0.05). As a result, the LPS-treated ARDS mice had a higher survival rate when they were treated with AstroRx.Conclusions: Our results demonstrate that the immunosuppressive activity of AstroRx cells support the application of AstroRx cells as a cell therapy treatment for ARDS. The immunoregulatory activity may also be a part of the mechanism of action of AstroRx reported in the amyotrophic lateral sclerosis (ALS) neurodegenerative disease.https://www.frontiersin.org/articles/10.3389/fmed.2021.740071/fullARDSastrocytesimmune-modulationinflammationembryonic stem cells |
| spellingShingle | Michal Izrael Kfir Molakandov Ariel Revel Shalom Guy Slutsky Tehila Sonnenfeld Julia Miriam Weiss Michel Revel Michel Revel Astrocytes Downregulate Inflammation in Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome: Applicability to COVID-19 Frontiers in Medicine ARDS astrocytes immune-modulation inflammation embryonic stem cells |
| title | Astrocytes Downregulate Inflammation in Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome: Applicability to COVID-19 |
| title_full | Astrocytes Downregulate Inflammation in Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome: Applicability to COVID-19 |
| title_fullStr | Astrocytes Downregulate Inflammation in Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome: Applicability to COVID-19 |
| title_full_unstemmed | Astrocytes Downregulate Inflammation in Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome: Applicability to COVID-19 |
| title_short | Astrocytes Downregulate Inflammation in Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome: Applicability to COVID-19 |
| title_sort | astrocytes downregulate inflammation in lipopolysaccharide induced acute respiratory distress syndrome applicability to covid 19 |
| topic | ARDS astrocytes immune-modulation inflammation embryonic stem cells |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2021.740071/full |
| work_keys_str_mv | AT michalizrael astrocytesdownregulateinflammationinlipopolysaccharideinducedacuterespiratorydistresssyndromeapplicabilitytocovid19 AT kfirmolakandov astrocytesdownregulateinflammationinlipopolysaccharideinducedacuterespiratorydistresssyndromeapplicabilitytocovid19 AT arielrevel astrocytesdownregulateinflammationinlipopolysaccharideinducedacuterespiratorydistresssyndromeapplicabilitytocovid19 AT shalomguyslutsky astrocytesdownregulateinflammationinlipopolysaccharideinducedacuterespiratorydistresssyndromeapplicabilitytocovid19 AT tehilasonnenfeld astrocytesdownregulateinflammationinlipopolysaccharideinducedacuterespiratorydistresssyndromeapplicabilitytocovid19 AT juliamiriamweiss astrocytesdownregulateinflammationinlipopolysaccharideinducedacuterespiratorydistresssyndromeapplicabilitytocovid19 AT michelrevel astrocytesdownregulateinflammationinlipopolysaccharideinducedacuterespiratorydistresssyndromeapplicabilitytocovid19 AT michelrevel astrocytesdownregulateinflammationinlipopolysaccharideinducedacuterespiratorydistresssyndromeapplicabilitytocovid19 |